dc.contributor.author |
Makarasen A. |
|
dc.contributor.author |
Kuno M. |
|
dc.contributor.author |
Patnin S. |
|
dc.contributor.author |
Reukngam N. |
|
dc.contributor.author |
Khlaychan P. |
|
dc.contributor.author |
Deeyohe S. |
|
dc.contributor.author |
Intachote P. |
|
dc.contributor.author |
Saimanee B. |
|
dc.contributor.author |
Sengsai S. |
|
dc.contributor.author |
Boonsri P. |
|
dc.contributor.author |
Chaivisuthangkura A. |
|
dc.contributor.author |
Sirithana W. |
|
dc.contributor.author |
Techasakul S. |
|
dc.contributor.author |
Dr. |
|
dc.date.accessioned |
2021-04-05T03:04:46Z |
|
dc.date.available |
2021-04-05T03:04:46Z |
|
dc.date.issued |
2019 |
|
dc.identifier.issn |
21949379 |
|
dc.identifier.other |
2-s2.0-85075814506 |
|
dc.identifier.uri |
https://ir.swu.ac.th/jspui/handle/123456789/12655 |
|
dc.identifier.uri |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075814506&doi=10.1055%2fa-0968-1150&partnerID=40&md5=ff3b3822d05ec10d157aa7796904d722 |
|
dc.description.abstract |
In this study, amino-oxy-diarylquinolines were designed using structure-guided molecular hybridization strategy and fusing of the pharmacophore templates of nevirapine (NVP), efavirenz (EFV), etravirine (ETV, TMC125) and rilpivirine (RPV, TMC278). The anti-HIV-1 reverse transcriptase (RT) activity was evaluated using standard ELISA method, and the cytotoxic activity was performed using MTT and XTT assays. The primary bioassay results indicated that 2-amino-4-oxy-diarylquinolines possess moderate inhibitory properties against HIV-1 RT. Molecular docking results showed that 2-amino-4-oxy-diarylquinolines 8(a-d) interacted with the Lys101 and His235 residue though hydrogen bonding and interacted with Tyr318 residue though π-π stacking in HIV-1 RT. Furthermore, 8a and 8d were the most potent anti-HIV agents among the designed and synthesized compounds, and their inhibition rates were 34.0% and 39.7% at 1 μM concentration. Interestingly, 8a was highly cytotoxicity against MOLT-3 (acute lymphoblastic leukemia), with an IC 50 of 4.63±0.62 μg/mL, which was similar with that in EFV and TMC278 (IC 50 7.76±0.37 and 1.57±0.20 μg/ml, respectively). Therefore, these analogs of the synthesized compounds can serve as excellent bases for the development of new anti-HIV-1 agents in the near future. © 2019 Georg Thieme Verlag. All rights reserved. |
|
dc.subject |
4 (2',6' dimethyl 4' cyanophenoxy) 2 (4" cyanophenyl)aminoquinoline |
|
dc.subject |
4 (2',6' dimethyl 4' cyanophenoxy) 2 chloroquinoline |
|
dc.subject |
4 (2',6' dimethyl 4' cyanophenoxy) 6 (4'' cyanophenyl)aminoquinoline |
|
dc.subject |
4 (2',6' dimethyl 4' cyanophenoxy) 6 nitroquinoline |
|
dc.subject |
4 (2',6' dimethyl 4' formylphenoxy) 2 (4'' cyanophenyl)aminoquinoline |
|
dc.subject |
4 (2',6' dimethyl 4' formylphenoxy) 2 chloroquinoline |
|
dc.subject |
4 (2',6' dimethyl 4' formylphenoxy) 6 (4" cyanophenyl)aminoquinoline |
|
dc.subject |
4 (2',6' dimethyl 4' formylphenoxy) 6 nitroquinoline |
|
dc.subject |
4 (4' cyanophenoxy) 2 (4" cyanophenyl)aminoquinoline |
|
dc.subject |
4 (4' cyanophenoxy) 2 chloroquinoline |
|
dc.subject |
4 (4' cyanophenoxy) 6 (4'' cyanophenyl)aminoquinoline |
|
dc.subject |
4 (4' cyanophenoxy) 6 nitroquinoline |
|
dc.subject |
4 (4' formylphenoxy) 2 (4" cyanophenyl)aminoquinoline |
|
dc.subject |
4 (4' formylphenoxy) 2 chloroquinoline |
|
dc.subject |
4 (4' formylphenoxy) 6 (4'' cyanophenyl)aminoquinoline |
|
dc.subject |
4 (4' formylphenoxy) 6 nitroquinoline |
|
dc.subject |
anti human immunodeficiency virus agent |
|
dc.subject |
antileukemic agent |
|
dc.subject |
doxorubicin |
|
dc.subject |
efavirenz |
|
dc.subject |
etoposide |
|
dc.subject |
etravirine |
|
dc.subject |
nevirapine |
|
dc.subject |
nonnucleoside reverse transcriptase inhibitor |
|
dc.subject |
quinoline derivative |
|
dc.subject |
rilpivirine |
|
dc.subject |
unclassified drug |
|
dc.subject |
anti human immunodeficiency virus agent |
|
dc.subject |
benzoxazine derivative |
|
dc.subject |
efavirenz |
|
dc.subject |
etravirine |
|
dc.subject |
nevirapine |
|
dc.subject |
pyridazine derivative |
|
dc.subject |
quinoline derivative |
|
dc.subject |
reverse transcriptase, Human immunodeficiency virus 1 |
|
dc.subject |
rilpivirine |
|
dc.subject |
RNA directed DNA polymerase |
|
dc.subject |
RNA directed DNA polymerase inhibitor |
|
dc.subject |
antileukemic activity |
|
dc.subject |
antiviral activity |
|
dc.subject |
Article |
|
dc.subject |
cell viability |
|
dc.subject |
comparative study |
|
dc.subject |
concentration response |
|
dc.subject |
controlled study |
|
dc.subject |
cytotoxicity |
|
dc.subject |
drug conformation |
|
dc.subject |
drug cytotoxicity |
|
dc.subject |
drug design |
|
dc.subject |
drug potency |
|
dc.subject |
drug protein binding |
|
dc.subject |
drug structure |
|
dc.subject |
drug synthesis |
|
dc.subject |
enzyme inhibition |
|
dc.subject |
enzyme linked immunosorbent assay |
|
dc.subject |
human |
|
dc.subject |
human cell |
|
dc.subject |
Human immunodeficiency virus 1 |
|
dc.subject |
hydrogen bond |
|
dc.subject |
IC50 |
|
dc.subject |
molecular docking |
|
dc.subject |
molecular hybridization |
|
dc.subject |
MOLT-3 cell line |
|
dc.subject |
MRC-5 cell line |
|
dc.subject |
MTT assay |
|
dc.subject |
pharmacophore |
|
dc.subject |
structure activity relation |
|
dc.subject |
XTT assay |
|
dc.subject |
chemistry |
|
dc.subject |
drug effect |
|
dc.subject |
Human immunodeficiency virus 1 |
|
dc.subject |
Human immunodeficiency virus infection |
|
dc.subject |
metabolism |
|
dc.subject |
molecular docking |
|
dc.subject |
tumor cell line |
|
dc.subject |
Anti-HIV Agents |
|
dc.subject |
Benzoxazines |
|
dc.subject |
Cell Line, Tumor |
|
dc.subject |
Diarylquinolines |
|
dc.subject |
HIV Infections |
|
dc.subject |
HIV Reverse Transcriptase |
|
dc.subject |
HIV-1 |
|
dc.subject |
Humans |
|
dc.subject |
Molecular Docking Simulation |
|
dc.subject |
Nevirapine |
|
dc.subject |
Pyridazines |
|
dc.subject |
Reverse Transcriptase Inhibitors |
|
dc.subject |
Rilpivirine |
|
dc.title |
Molecular Docking Studies and Synthesis of Amino-oxy-diarylquinoline Derivatives as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors |
|
dc.type |
Article |
|
dc.rights.holder |
Scopus |
|
dc.identifier.bibliograpycitation |
Drug Research. Vol 69, No.12 (2019), p.671-682 |
|
dc.identifier.doi |
10.1055/a-0968-1150 |
|